Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models.

Autor: Hasegawa S; Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka Higashi, Fujisawa 251-8555, Japan. Electronic address: shigeo.hasegawa@axcelead.com., Watanabe S; Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka Higashi, Fujisawa 251-8555, Japan. Electronic address: swatan21@ITS.JNJ.com., Fujimoto S; Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka Higashi, Fujisawa 251-8555, Japan. Electronic address: shinji.fujimoto@takeda.com., Kondo S; Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka Higashi, Fujisawa 251-8555, Japan. Electronic address: shinichi.kondou@takeda.com., Nishi T; Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka Higashi, Fujisawa 251-8555, Japan. Electronic address: tnishi@ovidrx.com.

Publikováno v: Neuroscience research [Neurosci Res] 2024 Nov; Vol. 208, pp. 29-38. Date of Electronic Publication: 2024 Jun 17.

Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.

Autor: Yin W; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Ballard TE; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Zhu SX; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Hsiao S; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Chen H; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Li Y; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Chowdhury SK; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Stevenson A; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Hui T; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Hunt A; Celerion, Lincoln, Nebraska, USA., Asgharnejad M; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA., Han S; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Feb; Vol. 90 (2), pp. 516-527. Date of Electronic Publication: 2023 Nov 12.

Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis.

Autor: Tsitsou-Kampeli A; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel. Electronic address: afroditi.tsitsou-kampeli@weizmann.ac.il., Suzzi S; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel. Electronic address: stefano.suzzi@pasteur.fr., Kenigsbuch M; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Satomi A; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel; Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan., Strobelt R; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel., Singer O; Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel., Feldmesser E; Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel., Purnapatre M; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel., Colaiuta SP; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel., David E; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Cahalon L; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel., Hahn O; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Wyss-Coray T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Shaul Y; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel., Amit I; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Schwartz M; Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel. Electronic address: michal.schwartz@weizmann.ac.il.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 Nov 21; Vol. 4 (11), pp. 101278. Date of Electronic Publication: 2023 Nov 08.

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice

Autor: Barker-Haliski, Melissa, Nishi, Toshiya, White, H. Steve

Publikováno v: In Neuropharmacology 1 January 2023 222

Preclinical characterization of [¹⁸F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase.

Autor: Koike, Tatsuki¹ tatsuki.koike@takeda.com, Constantinescu, Cristian C.², Ikeda, Shuhei¹, Nishi, Toshiya¹, Sunahara, Eiji¹, Miyamoto, Maki¹, Cole, Patricia³, Barret, Olivier², Alagille, David², Papin, Caroline², Morley, Thomas², Fowles, Krista⁴, Seibyl, John², Tamagnan, Gilles^2,4, Kuroita, Takanobu¹

Publikováno v: European Journal of Nuclear Medicine & Molecular Imaging. Mar2022, Vol. 49 Issue 4, p1148-1156. 9p. 1 Color Photograph, 2 Charts, 4 Graphs.